Correlation of Peripheral Blood Parameters and Immune-Related Adverse Events with the Efficacy of Immune Checkpoint Inhibitors

Table 1

Baseline characteristics of the patients.

Variable		Number of patients/Value	Percentage (%)
Gender	Male	80	77.67
	Female	23	22.33
Age	Median	61	—
	Scope	24–77
ECOG PS	0	17	16.50
	1	86	83.50
Body mass index	Mean value	23.4	—
	Scope	15.8–31.2
Tumor type	Lung cancer	51	49.51
	Melanoma	15	14.56
	Esophageal cancer	11	10.68
	Liver cancer	9	8.74
	Urothelial carcinoma	7	6.80
	Gastric cancer	5	4.85
	Other types of tumors	5	4.85
Distant metastasis	No distant organ metastasis	65	63.10
	One or more distant metastatic cancers	38	36.90
Prior therapy	Chemotherapy	67	65.05
	Radiotherapy	22	21.36
	Targeted therapy	8	7.77
	Immunotherapy	3	2.91
	Other therapies (interferon therapy and interventional/radiofrequency ablation therapy)	9	8.74
Treatment lines	First-line	26	25.24
	Nonfirst-line	77	74.76
Treatment regimen	Anti-PD-1	80	77.67
	Anti-PD-L1	13	12.62
	Anti-PD-1 + anti-CTLA-4	10	9.71

—Represents no usability data.